This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dahut, W. L. Articles by Figg, W. D. Search for Related Content PubMed PubMed Citation Articles by Dahut, W. L. Articles by Figg, W. D.

A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer

Authors' Affiliations: ¹ Clinical Pharmacology Program, ² Medical Oncology Branch, and ³ Biostatistics and Data Management Section, Center for Cancer Research, and the ⁴ Cancer Therapy and Evaluation Program, ⁵ National Cancer Institute, Bethesda, Maryland; and ⁶ Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia

Requests for reprints: William D. Figg, Medical Oncology Branch, National Cancer Institute, Building 10, Room 5A01, 9000 Rockville Pike, Bethesda, MD 20892. Phone: 301-402-3623; Fax: 301-402-8606; E-mail: wdfigg{at}helix.nih.gov.

Purpose: To determine if sorafenib is associated with a 4-month probability of progression-free survival, which is consistent with 50%, as determined by clinical, radiographic, and prostate-specific antigen (PSA) criteria in patients with metastatic androgen-independent prostate cancer (AIPC).

Experimental Design: Patients with progressive metastatic AIPC were enrolled in an open-label, single-arm phase II study. Sorafenib was given continuously at a dose of 400 mg orally twice daily in 28-day cycles. Clinical assessment and PSA measurement were done every cycle whereas radiographic measurements were carried out every two cycles.

Results: Twenty-two patients were enrolled in the study to date, completing a planned first stage of the trial. Baseline patient characteristics included a median age of 63.9 years (range, 50-77 years), Gleason score of 9 (range, 4-9.5), and PSA concentration of 53.3 ng/mL (range, 2-1,905 ng/mL). Fifty-nine percent of patients had received one prior chemotherapy regimenn. Of the 21 patients with progressive disease, 13 progressed only by PSA criteria in the absence of evidence of clinical and radiographic progression. Two patients were found to have dramatic reduction of bone metastatic lesions as shown by bone scan, although they met PSA progression criteria at the time when scans were obtained. Toxicities likely related to treatment included one grade 3 hypertension; one grade 3 hand-foot syndrome; and grade 1/2 toxicities: fatigue, anorexia, hypertension, skin rash, nausea, and diarrhea. Results from in vitro studies suggested that PSA is not a good marker of sorafenib activity. The geometric mean exposure (AUC_0-12) and maximum concentration (C_max) were 9.76 h mg/L and 1.28 mg/L, respectively. The time to maximum concentration (t_max) and accumulation ratio (after second dose) ranged from 2 to 12 h and 0.68 to 6.43, respectively.

Conclusions: Sorafenib is relatively well tolerated in AIPC with two patients showing evidence of improved bony metastatic lesions. Interpretation of this study is complicated by discordant radiographic and PSA responses. PSA may not be an adequate biomarker for monitoring sorafenib activity. Based on these observations, further investigation using only clinical and radiographic end points as progression criteria is warranted. Accrual to the second stage of trial is ongoing.

This article has been cited by other articles:

				S. Halabi, N. J. Vogelzang, S.-S. Ou, K. Owzar, L. Archer, and E. J. Small Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer J. Clin. Oncol., June 10, 2009; 27(17): 2766 - 2771. [Abstract] [Full Text] [PDF]

				M. Dror Michaelson, M. M. Regan, W. K. Oh, D. S. Kaufman, K. Olivier, S. Z. Michaelson, B. Spicer, C. Gurski, P. W. Kantoff, and M. R. Smith Phase II study of sunitinib in men with advanced prostate cancer Ann. Onc., May 1, 2009; 20(5): 913 - 920. [Abstract] [Full Text] [PDF]

				N. S. Azad, J. B. Aragon-Ching, W. L. Dahut, M. Gutierrez, W. D. Figg, L. Jain, S. M. Steinberg, M. L. Turner, E. C. Kohn, and H. H. Kong Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy Clin. Cancer Res., February 15, 2009; 15(4): 1411 - 1416. [Abstract] [Full Text] [PDF]

				G. Colloca, F. Checcaglini, and A. Venturino About sorafenib in castration-resistant prostate cancer Ann. Onc., October 1, 2008; 19(10): 1812 - 1813. [Full Text] [PDF]

				G. Gravis, F. Bladou, N. Salem, A. Goncalves, B. Esterni, J. Walz, S. Bagattini, M. Marcy, S. Brunelle, and P. Viens Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer Ann. Onc., September 1, 2008; 19(9): 1624 - 1628. [Abstract] [Full Text] [PDF]